Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.61 |
| ▸ | CA2 | P00918 | 1/20 | 0.61 |
| ▸ | LCK | P06239 | 9/20 | 0.46 |
| ▸ | GLS | O94925 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.39 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15861545 | 0.83 | CA1 (0.58) | CA1CA2LCKGLSALDH1A1 | |
| SCHEMBL15386264 | 0.83 | CA1 (0.61) | CA1CA2LCKALDH1A1SMN1; SMN2 | |
| SCHEMBL283195 | 0.81 | CA1 (0.60) | CA1CA2ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL970072 | 0.81 | CA1 (0.60) | CA1CA2LCKGLSALDH1A1 | |
| SCHEMBL8834429 | 0.80 | ALDH1A1 (0.63) | CA1CA2GLSALDH1A1SMN1; SMN2 | |
| SCHEMBL31421146 | 0.79 | CA1 (0.57) | CA1CA2GLSALDH1A1SMN1; SMN2 | |
| SCHEMBL31377111 | 0.76 | CA1 (0.55) | CA1CA2GLSALDH1A1SMN1; SMN2 | |
| SCHEMBL1691097 | 0.76 | CA1 (0.55) | CA1CA2LCKGLSALDH1A1 | |
| SCHEMBL27879248 | 0.76 | SMN1; SMN2 (0.61) | CA1CA2GLSALDH1A1SMN1; SMN2 | |
| SCHEMBL150084 | 0.76 | LCK (0.58) | CA1CA2LCKPI4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022114-A1 | N-(5-SUBSTITUTED-[(1,3,4-THIADIAZOLYL) OR (1,3-THIAZOLYL)](SUBSTITUTED)CARBOXAMIDE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING THE AMIDE COMPOUNDS AND OF THEIR USE | GILEAD SCIENCES, INC. | 2026-01-22 | — | — | US | disclosed |
| EP-4594316-A1 | N-(5-SUBSTITUTED-[(1,3,4-THIADIAZOLYL) OR (1,3-THIAZOLYL)](SUBSTITUTED)CARBOXAMIDE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING THE AMIDE COMPOUNDS AND OF THEIR USE | Repare Therapeutics Inc. (CA) | 2025-08-06 | — | — | EP | disclosed |
| US-20250026748-A1 | N-(5-SUBSTITUTED-[(1,3,4-THIADIAZOLYL) OR (THIAZOLYL)])(SUBSTITUTED)CARBOXAMIDE COMPOUNDS AND USE THEREOF FOR INHIBITING HUMAN POLYMERASE THETA | REPARE THERAPEUTICS INC. (CA) | 2025-01-23 | — | — | US | disclosed |
| EP-3164406-B1 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | QPEX BIOPHARMA INC (US) | 2024-12-25 | — | — | EP | disclosed |
| WO-2024182380-A2 | SUBSTITUTED THIADIAZOLYL COMPOUNDS | CYTEIR THERAPEUTICS, INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| US-20240277683-A1 | COMPOUNDS | CTXT PTY LTD (AU) | 2024-08-22 | — | — | US | disclosed |
| CN-118355015-A | N- (5-substituted- [ (1, 3, 4-thiadiazole) or (thiazolyl) ]) (substituted) carboxamide compounds for inhibiting human polymerase θ and uses thereof | 修复治疗公司 | 2024-07-16 | — | — | CN | disclosed |
| WO-2024129763-A1 | MODULATORS OF TNF-α ACTIVITY | FORWARD THERAPEUTICS, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| WO-2024069592-A1 | N-(5-SUBSTITUTED-[(L,3,4-THIADIAZOLYL) OR (L,3-THIAZOLYL)](SUBSTITUTED)CARBOXAMIDE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING THE AMIDE COMPOUNDS AND OF THEIR USE | REPARE THERAPEUTICS INC. (CA) | 2024-04-04 | — | — | WO | disclosed |
| US-11911372-B2 | Compounds | CTXT PTY LTD (AU) | 2024-02-27 | — | — | US | disclosed |
| US-11911372-B2 | Compounds | CTXT PTY LTD (AU) | 2024-02-27 | — | — | US | disclosed |
| US-11911372-B2 | Compounds | CTXT PTY LTD (AU) | 2024-02-27 | — | — | US | disclosed |
| US-20230134869-A1 | CRYSTAL FORM OF FREE ALKALI OF NITROGEN-CONTAINING AROMATIC DERIVATIVES | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2023-05-04 | — | — | US | disclosed |
| US-20230061891-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| EP-4129987-A1 | CRYSTAL FORM OF FREE ALKALI OF NITROGEN-CONTAINING AROMATIC DERIVATIVES | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2023-02-08 | — | — | EP | disclosed |
| US-20210213004-A1 | Compounds | CTXT PTY LTD (AU) | 2021-07-15 | — | — | US | disclosed |
| US-10206937-B2 | Boronic acid derivatives and therapeutic uses thereof | QPEX BIOPHARMA, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20170136047-A1 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | REMPEX PHARMACEUTICALS, INC. (US) | 2017-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022114-A1 | N-(5-SUBSTITUTED-[(1,3,4-THIADIAZOLYL) OR (1,3-THIAZOLYL)](SUBSTITUTED)CARBOXAMIDE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING THE AMIDE COMPOUNDS AND OF THEIR USE | POLK, POLQ, POLB | CA1 3220/4885CA2 1653/4885LCK 2059/4885 |
| US-20250026748-A1 | N-(5-SUBSTITUTED-[(1,3,4-THIADIAZOLYL) OR (THIAZOLYL)])(SUBSTITUTED)CARBOXAMIDE COMPOUNDS AND USE THEREOF FOR INHIBITING HUMAN POLYMERASE THETA | POLA1, POLL, POLD1 | CA1 1088/4885CA2 3161/4885LCK 2651/4885 |
| US-20240277683-A1 | COMPOUNDS | SLC10A1, ABCB11, REN | CA1 827/4885CA2 466/4885LCK 1758/4885 |
| US-10206937-B2 | Boronic acid derivatives and therapeutic uses thereof | BCL6B, BTD, BCL6 | CA1 1317/4885CA2 287/4885LCK 3219/4885 |
| US-20170136047-A1 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | BCL6B, BTD, BCL6 | CA1 1317/4885CA2 287/4885LCK 3219/4885 |
| US-20230061891-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | CA1 4785/4885CA2 4592/4885LCK 3080/4885 |
| US-20210213004-A1 | Compounds | SLC10A1, ABCB11, REN | CA1 764/4885CA2 429/4885LCK 2248/4885 |
| US-20230134869-A1 | CRYSTAL FORM OF FREE ALKALI OF NITROGEN-CONTAINING AROMATIC DERIVATIVES | PTPN22, PTPN2, PTPN5 | CA1 642/4885CA2 134/4885LCK 23/4885 |
| US-11911372-B2 | Compounds | SLC10A1, ABCB11, REN | CA1 764/4885CA2 429/4885LCK 2248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.